They found that patients with high AR/ER (>1.75, third quartile) had higher circulating testosterone levels and significantly worse DFS, which was a result validated in the Cancer Genome Atlas (TCGA) and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) databases. The gene discussed is AR; the disease is breast cancer.